Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Late-occurring and long-circulating metabolites of GABAAα2,3 receptor modulator AZD7325 involving metabolic cyclization and aromatization: relevance to MIST analysis and application for patient compliance

Chungang Gu, Markus Artelsmair, Charles S Elmore, Richard J Lewis, Patty Davis, James E Hall, Bruce T Dembofsky, Greg Christoph, Mark A Smith, Marc Chapdelaine and Maria Sunzel
Drug Metabolism and Disposition January 8, 2018, dmd.117.078873; DOI: https://doi.org/10.1124/dmd.117.078873
Chungang Gu
1 AstraZeneca R&D Boston;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: chuck.gu@biogen.com
Markus Artelsmair
2 AstraZeneca R&D Gothenburg;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles S Elmore
2 AstraZeneca R&D Gothenburg;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard J Lewis
2 AstraZeneca R&D Gothenburg;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patty Davis
3 AstraZeneca R&D Wilmington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James E Hall
3 AstraZeneca R&D Wilmington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruce T Dembofsky
3 AstraZeneca R&D Wilmington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Greg Christoph
3 AstraZeneca R&D Wilmington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark A Smith
3 AstraZeneca R&D Wilmington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Chapdelaine
3 AstraZeneca R&D Wilmington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Sunzel
3 AstraZeneca R&D Wilmington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

AZD7325 [4-amino-8-(2-fluoro-6-methoxyphenyl)-N-propylcinnoline-3-carboxamide] is a selective GABAAα2,3 receptor modulator intended for the treatment of anxiety disorders through oral administration. An interesting metabolic cyclization and aromatization pathway led to the tricyclic core of M9, i.e. 2-ethyl-7-(2-fluoro-6-methoxyphenyl)pyrimido[5,4-c]cinnolin-4(3H)-one. Further oxidative metabolism generated M10 via O-demethylation and M42 via hydroxylation. An authentic standard of M9 was synthesized to confirm the novel structure of M9 and that of M10 and M42 by liver microsomal incubation of the M9 standard. Metabolites M9, M10 and M42 were either minor or absent in plasma samples after a single dose, however, all became major metabolites in human and preclinical animal plasma after repeated doses, and circulated in humans longer than 48 h after the end of seven repeated doses. The absence of these long circulating metabolites from selected patients' plasma samples was used to demonstrate patient non-compliance as the cause of unexpected lack of drug exposure in some patients during a Phase IIb outpatient clinical study. The observation of late-occurring and long-circulating metabolites demonstrates the need to collect plasma samples at steady state after repeated doses when conducting metabolite analysis for the safety testing of drug metabolites. All 12 major non-conjugate metabolites of AZD7325 observed in human plasma at steady state were also observed in dog, rat, and mouse plasma samples collected from 3-month safety studies and at higher exposures in the animals than humans. This eliminated concern about human specific or disproportional metabolites.

  • animal/nonclinical/preclinical
  • HPLC
  • human/clinical
  • mass spectrometry/MS
  • metabolite identification
  • NMR
  • UPLC
  • The American Society for Pharmacology and Experimental Therapeutics
Next
Back to top

In this issue

Drug Metabolism and Disposition: 50 (6)
Drug Metabolism and Disposition
Vol. 50, Issue 6
1 Jun 2022
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Late-occurring and long-circulating metabolites of GABAAα2,3 receptor modulator AZD7325 involving metabolic cyclization and aromatization: relevance to MIST analysis and application for patient compliance
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Late-occurring and long-circulating metabolites of GABAAα2,3 receptor modulator AZD7325 involving metabolic cyclization and aromatization: relevance to MIST analysis and application for patient compliance

Chungang Gu, Markus Artelsmair, Charles S Elmore, Richard J Lewis, Patty Davis, James E Hall, Bruce T Dembofsky, Greg Christoph, Mark A Smith, Marc Chapdelaine and Maria Sunzel
Drug Metabolism and Disposition January 8, 2018, dmd.117.078873; DOI: https://doi.org/10.1124/dmd.117.078873

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Late-occurring and long-circulating metabolites of GABAAα2,3 receptor modulator AZD7325 involving metabolic cyclization and aromatization: relevance to MIST analysis and application for patient compliance

Chungang Gu, Markus Artelsmair, Charles S Elmore, Richard J Lewis, Patty Davis, James E Hall, Bruce T Dembofsky, Greg Christoph, Mark A Smith, Marc Chapdelaine and Maria Sunzel
Drug Metabolism and Disposition January 8, 2018, dmd.117.078873; DOI: https://doi.org/10.1124/dmd.117.078873
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Human ADME properties of abrocitinib
  • Impact of physiological microenvironments on HepaRG cells
  • New Dog, Cat, and Pig P450 2J Enzymes
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics